Evofem Biosciences Company
.jpg)
Evofem is a biotechnology company that develops reproductive and contraceptive care products for women worldwide. Its first commercial product, Phexxi vaginal gel, is for the prevention of pregnancy. Phexxi is hormone-free, female-controlled, on-demand prescription contraceptive gel. Its pipeline product candidate, EVO100, is being evaluated for the prevention of chlamydia and gonorrhea - two of the pervasive sexually transmitted diseases in the United States.
Investors
.jpg)
%20.jpg)
Connections from
Total Funding:
$444,200,000
Acquisitions Number:
1
Headquarters:
San Diego, California, United States
Funding Status:
IPO
Employee Number:
101-250
Estimated Revenue:
$1M to $10M
Last Funding Type:
Post-IPO Equity
Technology:
Specific disorder-related
Last Funding Date:
2021-10-12
Investors Number:
12
Founded Date:
01-01-2009
Industry:
Reproductive Health & Contraception